Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B
- 1 December 2005
- journal article
- editorial
- Published by Elsevier in Journal of Hepatology
- Vol. 43 (6) , 920-923
- https://doi.org/10.1016/j.jhep.2005.09.003
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2005
- 36 Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)Journal of Hepatology, 2005
- Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virusGastroenterology, 2004
- Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B1Gastroenterology, 2004
- A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysisJournal of Hepatology, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis BNew England Journal of Medicine, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis BNew England Journal of Medicine, 2003
- Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeksHepatology, 2002
- Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot studyThe Lancet, 2001